Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Cell Division Protein FtsZ (ftsz) Overview | 6 | 1 |
Therapeutics Development | 7 | 3 |
Cell Division Protein FtsZ (ftsz) Products under Development by Stage of Development | 7 | 1 |
Cell Division Protein FtsZ (ftsz) Products under Development by Therapy Area | 8 | 1 |
Cell Division Protein FtsZ (ftsz) Products under Development by Indication | 9 | 1 |
Cell Division Protein FtsZ (ftsz) Pipeline Products Glance | 10 | 1 |
Early Stage Products | 10 | 1 |
Cell Division Protein FtsZ (ftsz) Products under Development by Companies | 11 | 2 |
Cell Division Protein FtsZ (ftsz) Products under Development by Universities/Institutes | 13 | 2 |
Cell Division Protein FtsZ (ftsz) Therapeutics Assessment | 15 | 5 |
Assessment by Monotherapy/Combination Products | 15 | 1 |
Assessment by Mechanism of Action | 16 | 1 |
Assessment by Route of Administration | 17 | 2 |
Assessment by Molecule Type | 19 | 1 |
Cell Division Protein FtsZ (ftsz) Companies Involved in Therapeutics Development | 20 | 3 |
Gero Corp | 20 | 1 |
TAXIS Pharmaceuticals, Inc. | 21 | 1 |
Vichem Chemie Research Ltd. | 22 | 1 |
Cell Division Protein FtsZ (ftsz) Drug Profiles | 23 | 14 |
BIZ-20131 Drug Profile | 23 | 1 |
BIZ-20132 Drug Profile | 24 | 1 |
BIZ-20133 Drug Profile | 25 | 1 |
chrysophaentin Drug Profile | 26 | 1 |
SBP-17GA20 Drug Profile | 27 | 1 |
Small Molecules to Inhibit FtsZ for MRSA Infections Drug Profile | 28 | 1 |
Small Molecules to Inhibit FtsZ for Tuberculosis Drug Profile | 29 | 1 |
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections Drug Profile | 30 | 1 |
TXA-497 Drug Profile | 31 | 1 |
TXA-709 Drug Profile | 32 | 2 |
VCC-34236501 Drug Profile | 34 | 1 |
VCC-40402101 Drug Profile | 35 | 1 |
VCC-59946013 Drug Profile | 36 | 1 |
Cell Division Protein FtsZ (ftsz) Dormant Projects | 37 | 1 |
Cell Division Protein FtsZ (ftsz) Featured News &Press Releases | 38 | 5 |
Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection | 38 | 1 |
Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination | 39 | 1 |
Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance | 40 | 1 |
Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance | 41 | 2 |
Appendix | 43 | 2 |
Methodology | 43 | 1 |
Coverage | 43 | 1 |
Secondary Research | 43 | 1 |
Primary Research | 43 | 1 |
Expert Panel Validation | 43 | 1 |
Contact Us | 43 | 1 |
Disclaimer | 44 | 1 |